| BAC |
Report |
Diluted EPS |
BEAT |
pred ~$1.15 vs. cons $1.12 |
MEDIUM |
| BAC |
Report |
Net interest income (FTE) |
IN-LINE |
pred ~$16.18B vs. cons $16.10B |
MEDIUM |
| BAC |
Report |
Sales and trading revenue |
BEAT |
pred ~$6.22B vs. cons $6.15B |
MEDIUM |
| BAC |
Guide |
Net interest income growth |
BETTER |
guide ~8.0% vs. cons 7.5% (FY2026) |
MEDIUM |
| BAC |
Guide |
Net interest income |
BETTER |
guide ~$16.45B vs. cons $16.35B (3Q26) |
LOW |
| BAC |
Guide |
Operating leverage |
BETTER |
guide ~300 bps vs. cons 250 bps (FY2026) |
LOW |
| BAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.3% |
— |
MEDIUM |
| BAC |
Return |
5-day cumulative residual |
+2.1% (FOLLOW-THROUGH) |
The predicted FY2026 NII-growth midpoint of ~8.0% vs. consensus 7.5% should lift out-period EPS estimates; therefore, the 5-day residual reaches +2.1% vs. +1.3% on day 1 rather than fading after the reported beat. |
MEDIUM |